1. Sirolimus in combination with low-dose extended-release tacrolimus in kidney transplant recipients
- Author
-
Zhi-yu Zou, Lin-rui Dai, Yi-bo Hou, Chen-zhen Yu, Ren-jie Chen, Yan-yan Chen, Bin Liu, Hui-bo Shi, Nian-qiao Gong, Zhi-shui Chen, Song Chen, Sheng Chang, and Wei-jie Zhang
- Subjects
kidney transplantation ,immunosuppressant ,medication adherence ,sirolimus ,tacrolimus ,Medicine (General) ,R5-920 - Abstract
IntroductionMany challenges remain for long-term survival of renal allografts. Once-daily sirolimus (SRL) combined with low-dose extended-release tacrolimus (LER-TAC) may improve medication adherence and reduce the potential nephrotoxicity of calcineurin inhibitors (CNI) compared with standard immunosuppression regimens, thus potentially improving long-term graft survival.MethodsThis retrospective, observational, single-center, propensity score matching (PSM) study compared conversion to SRL combined with low-dose ER-TAC and mycophenolic acid (MPA) combined with standard-dose TAC in kidney transplant recipients. After PSM, there were 56 patients in each group. Efficacy, safety, and medication adherence were evaluated over 12 months.ResultsThere was no significant difference between the two groups in terms of graft and recipient survival and incidence of biopsy-proven acute rejection (p = 1.000), and none of the recipients developed dnDSA after conversion. The mean eGFR improved in SRL + LER-TAC group after conversion compared to before conversion (51.12 ± 20.1 ml/min/1.73 m2 vs. 56.97 ± 19.23 ml/min/1.73 m2, p
- Published
- 2023
- Full Text
- View/download PDF